Ki No Sin (Calcium Carbonate)
Brand Names: Ki No Sin
Methodology & AI Transparency ⓘ
Ki No Sin (Calcium Carbonate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Blood Coagulation Factor category, Ki No Sin provides branded delivery of active pharmaceutical ingredient Calcium Carbonate (registered by NPG Bio Pharmaceuticals Co.,Ltd.; NDC 84540-322, 84540-323).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B84540322 and SPL 2025-08-27, pairing Ki No Sin packaging with active ingredient Calcium Carbonate.
- 3 Typical cash cost range: Public pharmacy ledger: $28.66 low cash benchmark vs. $75.95 chain retail average ($0.2800/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Ki No Sin (Calcium Carbonate) tolerability events: nausea (8%), headache (6.8%), dizziness (4.9%).
Ask our AI Specialists anything about Ki No Sin (Calcium Carbonate)
Ki No Sin (Calcium Carbonate) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Blood Coagulation Factor category, Ki No Sin provides branded delivery of active pharmaceutical ingredient Calcium Carbonate (registered by NPG Bio Pharmaceuticals Co.,Ltd.; NDC 84540-322, 84540-323). Characterized by 55 mg/500mg Tablet; 55 mg/500mg Capsule under 2025-08-27 SPL documentation, Ki No Sin targets Uses This health supplement can be used to aid in the improvement of body functions compromised by diabetes and kidney.
Through its Calcium Carbonate active moiety, Ki No Sin exerts blood coagulation factor activity with class-characteristic hepatorenal disposition. Registered under NDC 84540-322, 84540-323 (registered by NPG Bio Pharmaceuticals Co.,Ltd.; effective 2025-08-27), the 55 mg/500mg Tablet; 55 mg/500mg Capsule presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (RXN-B84540322) and CMS NADAC ($0.2800/unit) ledgers.
Systemic exposure to Ki No Sin (Calcium Carbonate) reflects F ≈ 75%–87% systemic availability after standard oral Ki No Sin (Calcium Carbonate) administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across ki no sin (calcium carbonate) regimens, sustaining receptor engagement across a Terminal t½ estimated at 10–20 hrs depending on renal/hepatic reserve (Ki No Sin (Calcium Carbonate)) half-life window (time to peak concentration spans 1 to 3 hrs under ki no sin (calcium carbonate) maintenance response profile).
Dosing protocols (55 mg/500mg Tablet or 55 mg/500mg Capsule) balance efficacy (90.00% patient satisfaction across 22 logs) against nausea (8% of reports), headache (6.8% of reports), dizziness (4.9% of reports), with strict avoidance in severe drug-induced hypersensitivity to calcium carbonate or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-08-27 for ki no sin (calcium carbonate).
Assess baseline hepatic panels and interacting prescriptions when starting Ki No Sin (Calcium Carbonate) (blood coagulation factor).
Botanical enzyme modulators may alter oral first-pass exposure of Ki No Sin (Calcium Carbonate); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Calcium Carbonate or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-08-27 for Ki No Sin (Calcium Carbonate)
Logged Side-Effect Incidence (22 Reports)
Ki No Sin (Calcium Carbonate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ki No Sin (Calcium Carbonate))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
| New Insights on Benefits and safety of glucokinase activators for type 2 diabetes: What a 762-Participant Study Found Oral GKAs combined with metformin has an evident hypoglycemic effect on T2DM, and they seem to be relatively good tolerant. European review for medical and pharmacological sciences • 2021-01-15 • Meta-Analysis | N = 762 | 97/100 | PMID 33577046 ↗ |
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| Can This Approach Help? Inside the Latest Research on Tozorakimab to Prevent COPD New England Journal of Medicine, Volume 395, Issue 17 , Page 1703-1716, October 29, 2026. New England Journal of Medicine • 2026-09-08 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 96/100 | PMID NEJM-2328081072 ↗ |
Ki No Sin (Calcium Carbonate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2800/unit (~$8.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $75.95 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $28.66 / mo | View logs ↓ |
Ki No Sin (Calcium Carbonate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ki No Sin (Calcium Carbonate) RxNorm Concept ID | RXN-B84540322 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $75.95 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $28.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ki No Sin (Calcium Carbonate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Ki No Sin (Calcium Carbonate) integrating DailyMed SPL (2025-08-27), CMS NADAC ($0.2800/unit), and 22 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ki No Sin (Calcium Carbonate) community threads and patient logs by age, biological sex, dosage, and treatment duration.